Table 3.
Summarized Univariate HR of overall and subgroup analyses for CD44v6 on NSCLC survival
| N. of studies | Number of patients | Random effects HR (95% CIs) | Heterogeneity test | ||
|---|---|---|---|---|---|
|
| |||||
| chi-squared | I2 | P-value | |||
| Written Language | |||||
| English written | 5 | 0.88 (0.47-1.63) | 13.6 | 70.60% | 0.678 |
| Non English written | 10 | 2.05 (1.59-2.64) | 28.1 | 67.90% | 0.0001 |
| HR Estimate | |||||
| HR | 2 | 0.73 (0.16-2.3) | 9.58 | 89.6 | 0.683 |
| Sur. Curve | 13 | 1.83 (1.26-2.65) | 62.14 | 82.3 | 0.001 |
| Ethnicity | |||||
| Asian | 13 | 1.78 (1.34-2.35) | 48.26 | 75.10% | 0.0001 |
| Non-Asian | 2 | 0.53 (0.29-2.92) | 3.24 | 69.20% | 0.892 |
| Cutoff value | |||||
| 0% | 6 | 1.31 (0.73-2.35) | 23.54 | 78.80% | 0.369 |
| 10% | 4 | 2.03 (0.79-5.22) | 43.56 | 93.10% | 0.141 |
| Tumor stage | |||||
| I-II | 5 | 1.78 (0.78-4.09) | 23.85 | 83.20% | 0.7114 |
| I-III | 7 | 1.61 (1.01-2.58) | 43.52 | 86.20% | 0.0400 |
| Follow up time | |||||
| 36 months | 4 | 1.79 (0.9-3.58) | 12.05 | 75.10% | 0.0035 |
| 60 months | 9 | 1.82 (1.29-2.56) | 35.88 | 77.70% | 0.1915 |